miltefosine has been researched along with Cancer of Skin in 21 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A phase II trial evaluating 6% topical miltefosine solution was performed in 12 pretreated patients with cutaneous T-cell lymphoma." | 9.12 | A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma. ( Bérard, F; Coiffier, B; Dumontet, C; Gimonet, JF; Thomas, L, 2006) |
| "Patients with previously treated progressive cutaneous lesions from breast cancer were treated with miltefosine on a named-patient compassionate supply basis." | 9.09 | Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. ( Clive, S; Gardiner, J; Leonard, RC, 1999) |
| "To compare 6% miltefosine solution (Miltex; Asta Medica, Frankfurt, Germany), a new topical cytostatic drug, with placebo as palliative treatment for cutaneous metastases from breast cancer." | 9.09 | Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. ( David, M; Hardy, J; Houston, S; Leonard, R; Mansi, J; Simmonds, P; van Tienhoven, G, 2001) |
| "Miltefosine was selected because of its efficacy in breast cancer models." | 6.69 | Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer. ( Beijnen, JH; Mandjes, IA; Sindermann, H; ten Bokkel Huinink, WW; Terwogt, JM, 1999) |
| "Miltefosine therapy was discontinued in two patients due to nausea and in one patient due to skin toxicity." | 6.69 | Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. ( Bontenbal, M; Planting, AS; Seynaeve, C; Sindermann, H; Smorenburg, CH; Verweij, J, 2000) |
| "A phase II trial evaluating 6% topical miltefosine solution was performed in 12 pretreated patients with cutaneous T-cell lymphoma." | 5.12 | A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma. ( Bérard, F; Coiffier, B; Dumontet, C; Gimonet, JF; Thomas, L, 2006) |
| "Patients with previously treated progressive cutaneous lesions from breast cancer were treated with miltefosine on a named-patient compassionate supply basis." | 5.09 | Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. ( Clive, S; Gardiner, J; Leonard, RC, 1999) |
| "To compare 6% miltefosine solution (Miltex; Asta Medica, Frankfurt, Germany), a new topical cytostatic drug, with placebo as palliative treatment for cutaneous metastases from breast cancer." | 5.09 | Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. ( David, M; Hardy, J; Houston, S; Leonard, R; Mansi, J; Simmonds, P; van Tienhoven, G, 2001) |
| "Miltefosine was selected because of its efficacy in breast cancer models." | 2.69 | Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer. ( Beijnen, JH; Mandjes, IA; Sindermann, H; ten Bokkel Huinink, WW; Terwogt, JM, 1999) |
| "Miltefosine therapy was discontinued in two patients due to nausea and in one patient due to skin toxicity." | 2.69 | Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. ( Bontenbal, M; Planting, AS; Seynaeve, C; Sindermann, H; Smorenburg, CH; Verweij, J, 2000) |
| "Fungating wounds arise from primary, secondary or recurrent malignant disease and are associated with advanced cancer." | 2.50 | Topical agents and dressings for fungating wounds. ( Adderley, UJ; Holt, IG, 2014) |
| "Fungating wounds arise from primary, secondary or recurrent malignant disease and are associated with advanced cancer." | 2.44 | Topical agents and dressings for fungating wounds. ( Adderley, U; Smith, R, 2007) |
| "Widespread local recurrence of breast cancer, untreatable by surgery or radiation therapy, can present a serious therapeutic problem predominantly in patients refractory to systemic therapy." | 1.28 | Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. ( Eibl, H; Hilgard, P; Nagel, G; Peukert, M; Sindermann, H; Unger, C, 1990) |
| " After oral application He-PC was well absorbed from the intestine and metabolized in the liver by phospholipases C and D." | 1.28 | Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. ( Breiser, A; Damenz, W; Eibl, H; Engel, J; Fleer, EA; Hilgard, P; Kim, DJ; Nagel, G; Unger, C, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 8 (38.10) | 18.2507 |
| 2000's | 8 (38.10) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Prieto, MD | 1 |
| Uribe-Restrepo, AF | 1 |
| Arcos, D | 1 |
| Vargas, DA | 1 |
| Yosifov, DY | 1 |
| Kaloyanov, KA | 1 |
| Guenova, ML | 1 |
| Prisadashka, K | 1 |
| Balabanova, MB | 1 |
| Berger, MR | 1 |
| Konstantinov, SM | 1 |
| Adderley, UJ | 1 |
| Holt, IG | 1 |
| Viseux, V | 1 |
| Schoenlaub, P | 1 |
| Danhier, S | 1 |
| Vilque, JP | 1 |
| Plantin, P | 1 |
| Mahieu-Renard, L | 1 |
| Richard, MA | 1 |
| Dales, JP | 1 |
| Buscaylet, S | 1 |
| Lagrassa, S | 1 |
| Grob, JJ | 1 |
| Ragnarsson-Olding, B | 1 |
| Djureen-Mårtensson, E | 1 |
| Månsson-Brahme, E | 1 |
| Hansson, J | 1 |
| Dumontet, C | 1 |
| Thomas, L | 1 |
| Bérard, F | 1 |
| Gimonet, JF | 1 |
| Coiffier, B | 1 |
| Adderley, U | 1 |
| Smith, R | 1 |
| Dummer, R | 2 |
| Krasovec, M | 1 |
| Röger, J | 2 |
| Sindermann, H | 7 |
| Burg, G | 2 |
| Clive, S | 2 |
| Leonard, RC | 2 |
| Terwogt, JM | 1 |
| Mandjes, IA | 1 |
| Beijnen, JH | 1 |
| ten Bokkel Huinink, WW | 1 |
| Gardiner, J | 1 |
| Smorenburg, CH | 1 |
| Seynaeve, C | 1 |
| Bontenbal, M | 1 |
| Planting, AS | 1 |
| Verweij, J | 1 |
| Moĭseenko, VM | 1 |
| Orlova, RV | 1 |
| Ermakova, NA | 1 |
| Protsenko, SA | 1 |
| Leonard, R | 1 |
| Hardy, J | 1 |
| van Tienhoven, G | 1 |
| Houston, S | 1 |
| Simmonds, P | 1 |
| David, M | 1 |
| Mansi, J | 1 |
| Unger, C | 5 |
| Peukert, M | 3 |
| Hilgard, P | 4 |
| Engel, J | 3 |
| Eibl, H | 5 |
| Vogt, T | 1 |
| Becker, J | 1 |
| Hefner, H | 1 |
| Nagel, G | 2 |
| Damenz, W | 1 |
| Fleer, EA | 1 |
| Kim, DJ | 1 |
| Breiser, A | 2 |
| von Heyden, HW | 1 |
| Nagel, GA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluorescent Nanoparticles Conjugated Long-acting Somatostatin Analog for Potent Suppression and Bioimaging Breast Cancer[NCT04138342] | Phase 1 | 30 participants (Anticipated) | Interventional | 2019-09-15 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for miltefosine and Cancer of Skin
| Article | Year |
|---|---|
Topical agents and dressings for fungating wounds.
Topics: Anti-Infective Agents, Local; Antineoplastic Agents; Biological Dressings; Disease Progression; Fema | 2014 |
Topical agents and dressings for fungating wounds.
Topics: Anti-Infective Agents, Local; Antineoplastic Agents; Biological Dressings; Disease Progression; Fema | 2007 |
Hexadecylphosphocholine: a new and selective antitumor drug.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Drug Screening Assays, Antitumor; Female; Humans; | 1990 |
8 trials available for miltefosine and Cancer of Skin
| Article | Year |
|---|---|
A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; | 2006 |
Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Female; Hu | 1993 |
Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dr | 1999 |
Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Br | 1999 |
Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients.
Topics: Administration, Topical; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middl | 2000 |
[Treatment with Miltex for metastatic skin lesions in breast cancer] .
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Phosphorylcholine; Skin | 2000 |
Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Do | 2001 |
Topical application of hexadecylphosphocholine in patients with cutaneous lymphomas.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Ly | 1992 |
10 other studies available for miltefosine and Cancer of Skin
| Article | Year |
|---|---|
Case Report: Squamous Cell Carcinoma Referred for Mohs Surgery Found to be Cutaneous Leishmaniasis.
Topics: Antibodies, Protozoan; Antiprotozoal Agents; Carcinoma, Squamous Cell; Diagnosis, Differential; Fema | 2018 |
Alkylphosphocholines and curcumin induce programmed cell death in cutaneous T-cell lymphoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Blotting, Western; Caspases; Cell Line, Tumor; Cell Sur | 2014 |
[Multiple cutaneous plasmocytoma treated with topical applications of miltefosine].
Topics: Administration, Topical; Aged; Antineoplastic Agents; Female; Humans; Multiple Myeloma; Phosphorylch | 2004 |
[Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine].
Topics: Administration, Topical; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Leg; | 2005 |
Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Melanoma; Neo | 2005 |
Miltefosine in recurrent cutaneous breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Phosphorylcholi | 1997 |
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; | 1992 |
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dr | 1990 |
Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Choline; Drug Screening Assays, Antitumor; Female; | 1989 |
Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial.
Topics: Administration, Topical; Breast Neoplasms; Choline; Drug Evaluation; Female; Humans; Neoplasm Recurr | 1988 |